drugset / Trial / NCT05509361
Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label Phase III clinical study to evaluate the long-term safety and efficacy of AK101 injection in subjects with moderate-to-severe plaque psoriasis.
Timeline
- Start
- 2022-04-08
- Primary completion
- 2023-11-24
- Completion
- 2023-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBDAROKIMAB | Monoclonal antibody | 135 mg | Subcutaneous |